Analysts at Furey Research Partners assumed coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) in a research report issued to clients and investors on Wednesday. The firm set a “buy” rating and a $20.00 price target on the stock. Furey ... ...

64 people liked this